pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,730 catalysts · 5,159 phase readout · 2,286 8k filing · 315 pdufa · 256 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 14 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: earnings×type: pdufa×clear all
type
  • phase readout5,159
  • 8k filing2,286
  • pdufa315
  • earnings256
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›COMPLETEDphase readoutNCT06335329: Point-of-Care Ultrasound (POCUS) Findings and Impact on Vaping

Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Vaping

full page →ctgov ↗
›RECRUITINGphase readoutNCT06856902: BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

Sponsor: Technical University of Madrid. Phase: NA. Conditions: Cardiovascular Diseases, Endocrinology, Inmunology, Neurology, Oncology, Rare Diseases

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05831202: SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

Sponsor: Galaxy Therapeutics INC. Phase: PHASE3. Conditions: Intracranial Aneurysm

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06647602: Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

Sponsor: University Medical Center Groningen. Phase: . Conditions: Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine, Thyroid Hormones

full page →ctgov ↗
›COMPLETEDphase readoutNCT03969953: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Sponsor: The George Institute. Phase: PHASE3. Conditions: Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Sponsor: EMD Serono Research & Development Institute, Inc.. Phase: PHASE1. Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors

full page →ctgov ↗
›COMPLETEDphase readoutNCT03364153: Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Sponsor: Astellas Pharma Global Development, Inc.. Phase: PHASE2. Conditions: Stargardt's Macular Dystrophy

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07418372: Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences. Phase: PHASE1. Conditions: Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria, Pertussis, Pertussis Vaccines

full page →ctgov ↗
›RECRUITINGphase readoutNCT06361472: Contextual Factors-Enriched Standard Care on Mechanical Neck Pain

Sponsor: Universidad Nacional de la Matanza. Phase: NA. Conditions: Neck Pain

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06079372: Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Sponsor: Alexion Pharmaceuticals, Inc.. Phase: PHASE3. Conditions: Hypophosphatasia

full page →ctgov ↗
›COMPLETEDphase readoutNCT07112495: Maternal Burnout, Breastfeeding Self-Efficacy and Attachment Level

Sponsor: Sakarya University. Phase: NA. Conditions: Pregnancy

full page →ctgov ↗
›COMPLETEDphase readoutNCT07360639: The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment

Sponsor: Universitas Syiah Kuala. Phase: PHASE1. Conditions: Dry Skin, Xerosis Cutis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07368777: Comparison of Genotype-Based Dietary Counseling Versus Standard Dietary Counseling on Weight Loss and Fat Mass Reduction

Sponsor: Metropolitan College. Phase: NA. Conditions: Overweight, Overweight and Obesity, Adiposity

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07684677: Effect of Participating in a Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registries

Sponsor: Amager Hospital. Phase: NA. Conditions: Pregnancy Loss, Early, Major Depression, Anxiety, Stress (Psychology)

full page →ctgov ↗
›COMPLETEDphase readoutNCT03485677: Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Sponsor: Sanofi. Phase: PHASE3. Conditions: Gaucher's Disease Type I, Gaucher's Disease Type III

full page →ctgov ↗
›COMPLETEDphase readoutNCT05608577: RE-BLEED: A Digital Platform for Identifying Bleeding Patients - a Feasibility Study

Sponsor: University of Oxford. Phase: . Conditions: Hemorrhage, Trauma, Gastro Intestinal Bleeding

full page →ctgov ↗
›RECRUITINGphase readoutNCT07566377: Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Sponsor: Memorial Sloan Kettering Cancer Center. Phase: PHASE2. Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT04892277: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Sponsor: Mayo Clinic. Phase: PHASE1. Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06933875: Promoting Palliative Care for People With Heart Failure

Sponsor: Yale University. Phase: NA. Conditions: Heart Failure, Palliative Care

full page →ctgov ↗
›RECRUITINGphase readoutNCT07615257: Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control

Sponsor: Islamia University of Bahawalpur. Phase: NA. Conditions: Psoriasis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06087757: Clemastine Treatment in Individuals With Williams Syndrome

Sponsor: Sheba Medical Center. Phase: PHASE2. Conditions: Williams Syndrome

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Sponsor: Shanghai Zhongshan Hospital. Phase: PHASE1. Conditions: Biliary Tract Cancer, Candonilimab, Claudin 18.2

full page →ctgov ↗
›COMPLETEDphase readoutNCT06957301: Intrathecal Fentanyl and Dexmedetomidine Added to Bupivacaine for Subarachnoid Anaesthesia for Percutaneous Nephrolithotomy

Sponsor: Alexandria University. Phase: NA. Conditions: Percutaneous Nephrolithotomy (PCNL)

full page →ctgov ↗
›COMPLETEDphase readoutNCT06533501: Leucine Requirements During the Menstrual Cycle

Sponsor: University of British Columbia. Phase: NA. Conditions: Menstrual Cycle

full page →ctgov ↗
›RECRUITINGphase readoutNCT05608681: A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

Sponsor: Eupraxia Pharmaceuticals Inc.. Phase: PHASE1. Conditions: Eosinophilic Esophagitis

full page →ctgov ↗
›RECRUITINGphase readoutNCT03588481: IRIS- DESyne X2 in the IRIS-DES Registry

Sponsor: Seung-Jung Park. Phase: . Conditions: Coronary Stenosis, Coronary Occlusion, Coronary Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT06558981: Adjuvant Radiotherapy in High Risk Locally Advanced DTC

Sponsor: Fudan University. Phase: PHASE3. Conditions: Thyroid Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT06183281: Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

Sponsor: University of California, San Francisco. Phase: NA. Conditions: Chronic Pain

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07647081: The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women

Sponsor: Oklahoma State University Center for Health Sciences. Phase: NA. Conditions: Stress

full page →ctgov ↗
›COMPLETEDphase readoutNCT07470619: Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer

Sponsor: Near East University, Turkey. Phase: NA. Conditions: Nausea and Vomiting Chemotherapy-Induced, Meditation Training

full page →ctgov ↗
›WITHDRAWNphase readoutNCT03730467: Puncture Breast Abscess

Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: . Conditions: Breast Abscess

full page →ctgov ↗
›RECRUITINGphase readoutNCT04093167: Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Sponsor: Canadian Cancer Trials Group. Phase: PHASE2. Conditions: Lung Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT05235867: Secretin in Refeeding

Sponsor: University of California, Los Angeles. Phase: . Conditions: Anorexia in Adolescence

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07464067: Family Planning Methods Among Women in Assuit Egypt

Sponsor: Assiut University. Phase: . Conditions: Family Planning

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03839667: Intensive Diet and Physical Activity on Diabetes

Sponsor: Shanghai Jiao Tong University School of Medicine. Phase: NA. Conditions: Type2 Diabetes, Life Style

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03439267: Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events

Sponsor: Intermountain Health Care, Inc.. Phase: NA. Conditions: Cardiovascular Primary Prevention Strategy

full page →ctgov ↗
›RECRUITINGphase readoutNCT03144167: Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

Sponsor: Centre Hospitalier Universitaire, Amiens. Phase: NA. Conditions: Glioblastoma, Radiotherapy, Chemotherapy

full page →ctgov ↗
›COMPLETEDphase readoutNCT05372367: A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Sponsor: Boehringer Ingelheim. Phase: PHASE1. Conditions: Solid Tumors

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03467867: A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Sponsor: Georgetown University. Phase: PHASE2. Conditions: Chronic Lymphocytic Leukemia

full page →ctgov ↗
›RECRUITINGphase readoutNCT06633900: Naltrexone for Overdose Prevention

Sponsor: University of California, San Francisco. Phase: PHASE2. Conditions: Overdose Accidental

full page →ctgov ↗
›RECRUITINGphase readoutNCT06611007: Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

Sponsor: University Hospital, Grenoble. Phase: PHASE1. Conditions: Osteoarthritis

full page →ctgov ↗
›RECRUITINGphase readoutNCT06970392: Brief Sleep Intervention for Bedtime Resistance

Sponsor: Oregon Health and Science University. Phase: NA. Conditions: Child Sleep

full page →ctgov ↗
›RECRUITINGphase readoutNCT07220720: POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Sponsor: University of Florida. Phase: PHASE2. Conditions: Prostate

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07453420: Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.

Sponsor: Shalvata Mental Health Center. Phase: . Conditions: Anxiety, Depression - Major Depressive Disorder, Bipolar, Schizophenia Disorder

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07384520: Thrombus Composition in Cerebral Infarctions: Study of Its Association With Plasma Biomarkers, Treatment Efficacy, Etiology and Prognosis.

Sponsor: François Delvoye. Phase: . Conditions: Ischemic Stroke, Cerebral Veinous Thrombosis

full page →ctgov ↗
›COMPLETEDphase readoutNCT06792123: Effect of Virtual Reality Application Applied to Patients With Total Knee Replacement at Different Times

Sponsor: Özge İşeri. Phase: NA. Conditions: Anxiety, Recovery Quality

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06912659: The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib

Sponsor: Boehringer Ingelheim. Phase: . Conditions: Pulmonary Fibrosis

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT05462262: Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital. Phase: NA. Conditions: Coronary Artery Disease Progression

full page →ctgov ↗
›COMPLETEDphase readoutNCT06001346: CBT+ for Depression

Sponsor: University of Wisconsin, Madison. Phase: NA. Conditions: Major Depressive Disorder

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07469488: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China. Phase: PHASE4. Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction

full page →ctgov ↗
← prev
page 90 of 115
next →